Daniel Prior, MD
Assistant Professor of Pediatrics (Hematology/Oncology)About
Research
Publications
2026
Catastrophic Consequences of Bacillus Cereus–Contaminated Hematopoietic Stem Cells: Hemolytic Transfusion Reaction, Septic Shock, and Adaptive GVHD Prophylaxis in a Pediatric Allogeneic Transplant
Adekanye A, Agli J, Bowers A, Flagg A, Prior D, Krishnamurti L. Catastrophic Consequences of Bacillus Cereus–Contaminated Hematopoietic Stem Cells: Hemolytic Transfusion Reaction, Septic Shock, and Adaptive GVHD Prophylaxis in a Pediatric Allogeneic Transplant. Transplantation And Cellular Therapy 2026, 32: s613. DOI: 10.1016/j.jtct.2025.12.918.Peer-Reviewed Original ResearchGraft-versus-host diseaseContinuous renal replacement therapyHematopoietic cell transplantationGraft-versus-host disease prophylaxisHemolytic transfusion reactionsSeptic shockTransfusion reactionsGVHD prophylaxisMycophenolate mofetilPediatric casesOrgan dysfunctionAcute graft-versus-host diseaseStandard agentsStage 3 acute kidney injuryDonor hematopoietic cell transplantationAssociated with significant morbiditySevere aplastic anemiaPediatric hematopoietic cell transplantationTotal body irradiationAcute renal failureRenal replacement therapyAcute organ dysfunctionAggressive supportive careLife-threatening consequencesEmpiric vancomycin
2025
Comparison of Regimens Used for Allogeneic Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease
Prior D, Liang J, Deng Y, Shah N, Flagg A, Krishnamurti L. Comparison of Regimens Used for Allogeneic Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2025, 31: 594.e1-594.e13. PMID: 40379050, DOI: 10.1016/j.jtct.2025.05.004.Peer-Reviewed Original ResearchGraft-versus-host diseaseHematopoietic cell transplantationHLA-matched related donorSickle cell diseaseConditioning regimen intensityAnti-thymocyte globulinEFS ratesConditioning regimensRegimen intensityCell transplantationRate of chronic graft-versus-host diseaseRelated donorsChronic graft-versus-host diseaseHematopoietic cell transplantation regimensNon-myeloablative conditioning regimensAllogeneic hematopoietic cell transplantationCell diseaseComparison of regimensMyeloablative conditioning regimensNon-myeloablative conditioningNon-myeloablative regimensSickle cell disease patientsEvent-free survivalGraft-versus-hostAnti-thymocyteStandard‐Dose Versus High‐Dose Cisplatin for Intermediate/Poor‐Risk Extracranial Malignant Germ Cell Tumors: Re‐Analysis of Pediatric Oncology Group 9049 and Children's Cancer Group 8882 Trial Using Updated MaGIC Risk Stratification
Prior D, Yang J, Nuño M, Shaikh F, Frazier A, Pashankar F. Standard‐Dose Versus High‐Dose Cisplatin for Intermediate/Poor‐Risk Extracranial Malignant Germ Cell Tumors: Re‐Analysis of Pediatric Oncology Group 9049 and Children's Cancer Group 8882 Trial Using Updated MaGIC Risk Stratification. Pediatric Blood & Cancer 2025, 72: e31665. PMID: 40098231, PMCID: PMC12018124, DOI: 10.1002/pbc.31665.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCisplatinClinical Trials, Phase II as TopicEtoposideFemaleFollow-Up StudiesHumansMaleMediastinal NeoplasmsMulticenter Studies as TopicNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsPrognosisRetroperitoneal NeoplasmsRisk AssessmentSecondary Data AnalysisSurvival RateTesticular NeoplasmsConceptsGerm cell tumorsEvent-free survivalOverall survivalStandard of careRisk stratificationCell tumorsExtracranial malignant germ cell tumorsHigh-risk germ cell tumorsMalignant Germ Cell International ConsortiumRetroperitoneal germ cell tumorsOvarian germ cell tumorsMalignant germ cell tumorsHigh-dose cisplatinChildren's Cancer GroupYears of ageStatistically significant differenceMediastinal primaryGCT patientsIntergroup trialPoor riskHDPEBHigh-doseRandomized patientsAdolescent patientsPoor prognosis
2024
Large B‐cell lymphoma with mystery rearrangement: Applying Hi‐C to the detection of clinically relevant structural abnormalities
Prior D, Schmitt A, Louissaint A, Mata D, Massaro S, Nardi V, Xu M. Large B‐cell lymphoma with mystery rearrangement: Applying Hi‐C to the detection of clinically relevant structural abnormalities. British Journal Of Haematology 2024, 205: 1225-1229. PMID: 38924537, DOI: 10.1111/bjh.19611.Peer-Reviewed Original ResearchTherapeutic Targeting of DNA Repair Pathways in Pediatric Extracranial Solid Tumors: Current State and Implications for Immunotherapy
Zhao S, Prior D, Heske C, Vasquez J. Therapeutic Targeting of DNA Repair Pathways in Pediatric Extracranial Solid Tumors: Current State and Implications for Immunotherapy. Cancers 2024, 16: 1648. PMID: 38730598, PMCID: PMC11083679, DOI: 10.3390/cancers16091648.Peer-Reviewed Original ResearchDNA damage repair inhibitorsPediatric extracranial solid tumorDNA damage repair deficiencyExtracranial solid tumorSolid tumorsDNA damage repairResponse to immune checkpoint blockadeCombinations of DDR inhibitorsEnhance tumor immunogenicityImmune checkpoint blockadePediatric solid tumorsTherapeutic targetPediatric clinical trialsDNA damage repair pathwaysDDR pathwaysCheckpoint blockadeTumor immunogenicityDNA damagePediatric tumorsPotential therapeutic targetDDR inhibitorsClinical trialsTumorHuman cancersRepair DNA damageNormal Erythroid Precursors in Diamond-Blackfan Anemia: A Rare Case Highlighting Challenges That Remain
Prior D, Sowa A, Pashankar F. Normal Erythroid Precursors in Diamond-Blackfan Anemia: A Rare Case Highlighting Challenges That Remain. Journal Of Pediatric Hematology/Oncology 2024, 46: e195-e198. PMID: 38277626, DOI: 10.1097/mph.0000000000002820.Peer-Reviewed Original ResearchConceptsDiamond-Blackfan anemiaDiamond-BlackfanDiagnosis of Diamond-Blackfan anemiaInherited bone marrow failure syndromeBone marrow failure syndromesMarrow failure syndromesDiagnostically challenging casesFailure syndromeAtypical manifestationsSpontaneous remissionRare caseErythroid precursorsChallenging casesGenetic etiologyPhenotypic manifestationsAnemiaPatientsRemissionRelapseHypoplasiaSyndromeEtiologyDiagnosis
Clinical Care
Overview
Daniel Prior, MD, is a pediatric hematologist-oncologist and transplant physician who cares for children with blood cancers and complex blood disorders. He works with children and families facing high-risk or recurrent cancers, bone marrow failure syndromes, and conditions that affect red blood cells, such as sickle cell disease and other hemoglobin disorders. He also leads the Bone Marrow Failure program at Yale.
Dr. Prior’s clinical work focuses on helping children who may need or have received hematopoietic cell transplantation, sometimes called bone marrow or stem cell transplantation. He cares for patients before, during, and after transplant, monitoring them closely and adjusting treatment as their needs change. He understands that a serious diagnosis affects the whole family, and he strives to communicate clearly, answer questions, and guide families through each step of treatment.
As an assistant professor of pediatrics at Yale School of Medicine, Dr. Prior is a dedicated educator who teaches and mentors medical students, residents, and fellows. He enjoys collaborating with learners at all levels and working in a team-based environment to improve care for children with blood disorders and cancer.
Dr. Prior earned his medical degree from the University of Connecticut School of Medicine.
Clinical Specialties
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.